Optimi Health Welcomes Dr. Preston A. Chase as New Chief Science Officer
07 Noviembre 2023 - 6:30AM
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a
leading Canadian psychedelics drug research and formulation
company, is delighted to announce the appointment of Dr. Preston A.
Chase as the Company’s Chief Science Officer (“CSO”).
Dr. Chase is a distinguished Research &
Development (“R&D”) chemist and seasoned business professional
with an impressive academic and industrial track record spanning
over 25 years. His extensive experience includes pioneering the
development and commercialization of innovative products and
processes for both multinational corporations and startup ventures.
He holds a BSc from the University of Victoria and a PhD from the
University of Calgary, and a solid foundation in catalysis,
synthesis, and analytical chemistry. With over 30 peer-reviewed
scientific publications and numerous awarded and pending patents,
he brings a wealth of research expertise and a strong history of
commercial success to the Optimi Health team.
Optimi Health CEO Bill Ciprick conveyed his
excitement regarding Dr. Chase's addition to the team, remarking,
“Dr. Chase brings invaluable business acumen and a passion to
harness the potential of psychedelics for the betterment of people.
His adeptness in overcoming challenges and accelerating decisions
will propel Optimi's position as an industry frontrunner and help
us achieve our long-term goals.”
In his new role, Dr. Chase will take charge of
shaping and advancing research capabilities and delivering safe,
effective products to the nascent psychedelic market. His mandate
includes the critical task of establishing the scientific validity
and utility of Optimi's GMP psilocybin and MDMA drug candidates
while fostering transparent communication with scientific and
customer communities. He will also lead a core scientific team
throughout the development process, ensuring that the Company
continues to push the boundaries of innovation.
Further, his experience in analysis of
botanicals for medical use will support the integrity of Optimi’s
drug candidates and the robustness of the Company’s supply pathway,
ensuring that Optimi meets the highest standards of quality
assurance and regulatory compliance in cultivation and dose factor
for its customers.
Expressing his commitment to Optimi's mission,
Dr. Chase enthusiastically states, “I'm excited to be a part of a
venture with the potential to profoundly improve the lives of many.
I envision a promising future for Optimi Health and am eager to
guide our scientific pursuits toward pioneering
accomplishments.”
Optimi is also announcing the appointment of
Abigail Ranger who will join Dr. Chase's core science team on
November 1st as the Company's Analytical and GMP Laboratory
Manager. Ms. Ranger brings extensive professional experience in GMP
laboratory operations, research project development, and validation
protocols to Optimi.
As Dr. Chase assumes leadership of Optimi's
R&D and science-driven protocols, the Company extends its
appreciation to Justin Kirkland, the departing CSO, for his devoted
service to Optimi during the last two years. Mr. Kirkland will
continue his association with the Company as a project
consultant.
Optimi Health warmly welcomes both Dr. Chase and
Ms. Ranger to the Optimi team and anticipates an era of remarkable
scientific progress under their guidance.
www.optimihealth.ca
For further information or to request an
interview, please contact:Michael KyddInvestor RelationsEmail:
investors@optimihealth.ca Phone: +1 (902) 880 6121
ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF)
(FRA: 8BN)
Optimi Health Corp. is an end-to-end
Canadian-based drug researcher and formulator licensed by Health
Canada to produce and supply psychedelic substances such as
3,4-Methylenedioxymethamphetamine (“MDMA”) and natural, GMP-grade
psilocybin, as well as functional mushrooms that focus on the
health and wellness markets. Built with the purpose of producing
scalable psychedelic formulations for transformational human
experiences, the Company’s goal is to be the number one trusted,
compassionate supplier of safe drug products throughout the world.
Optimi’s products are grown at its two facilities comprising a
total of 20,000 square feet in Princeton, British Columbia, making
it the largest psilocybin and MDMA producer in North
America.FORWARD-LOOKING STATEMENTS
This news release contains forward‐looking
statements and forward‐looking information within the meaning of
Canadian securities legislation (collectively, “forward‐looking
statements”) that relate to Optimi’s current expectations and views
of future events. Any statements that express, or involve
discussions as to, expectations, beliefs, plans, objectives,
assumptions or future events or performance (often, but not always,
through the use of words or phrases such as “will likely result,”
“are expected to,” “expects,” “will continue,” “is anticipated,”
“anticipates,” “believes,” “estimated,” “intends,” “plans,”
“forecast,” “projection,” “strategy,” “objective,” and “outlook”)
are not historical facts and may be forward‐looking statements and
may involve estimates, assumptions and uncertainties which could
cause actual results or outcomes to differ materially from those
expressed in such forward‐looking statements. No assurance can be
given that these expectations will prove to be correct and such
forward‐looking statements included in this news release should not
be unduly relied upon. These statements speak only as of the date
of this news release.
Forward‐looking statements are based on a number
of assumptions and are subject to a number of risks and
uncertainties, many of which are beyond Optimi’s control, which
could cause actual results and events to differ materially from
those that are disclosed in or implied by such forward‐looking
statements. Such risks and uncertainties include, but are not
limited to, the impact and progression of the COVID‐19 pandemic and
other factors set forth under “Forward‐Looking Statements” and
“Risk Factors” in the Company’s Annual information Form dated
January 9, 2023, and other continuous disclosure filings available
under Optimi’s profile at www.sedarplus.ca. Optimi undertakes no
obligation to update or revise any forward‐looking statements,
whether as a result of new information, future events or otherwise,
except as may be required by law. New factors emerge from time to
time, and it is not possible for Optimi to predict all of them or
assess the impact of each such factor or the extent to which any
factor, or combination of factors, may cause results to differ
materially from those contained in any forward‐looking
statement.
Any forward‐looking statements contained in this
news release are expressly qualified in their entirety by this
cautionary statement.
Optimi Health (TG:8BN)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Optimi Health (TG:8BN)
Gráfica de Acción Histórica
De May 2023 a May 2024